A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas

Detalles Bibliográficos
Autores principales: Goswami, Trishna, Canelos, Paola, Parikh, Radhika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Poster Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288733/
http://dx.doi.org/10.1186/2051-1426-2-S3-P73
Descripción
Sumario:

Ejemplares similares